Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- PMID: 26210956
- DOI: 10.1016/j.drudis.2015.07.008
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
Abstract
Small-molecule kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising _targeted therapeutics. Here, we assess the key structural and physicochemical properties, _target selectivity and mechanism of function, and therapeutic indications of these approved inhibitors. Our analysis showed that >30% of approved SMKIs have a molecule weight (MW) exceeding 500 and all have a total ring count of between three and five. The assumption that type II inhibitors tend to be more selective than type I inhibitors has been proved to be unreliable. Although previous SMKI research was concentrated on tyrosine kinase inhibitors for cancer treatment, recent progress indicates diversification of SMKI research in terms of new _targets, mechanistic types, and therapeutic indications.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.Pharmacol Res. 2020 Feb;152:104609. doi: 10.1016/j.phrs.2019.104609. Epub 2019 Dec 17. Pharmacol Res. 2020. PMID: 31862477 Review.
-
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.Pharmacol Res. 2021 Mar;165:105463. doi: 10.1016/j.phrs.2021.105463. Epub 2021 Jan 26. Pharmacol Res. 2021. PMID: 33513356 Review.
-
Properties of FDA-approved small molecule protein kinase inhibitors.Pharmacol Res. 2019 Jun;144:19-50. doi: 10.1016/j.phrs.2019.03.006. Epub 2019 Mar 13. Pharmacol Res. 2019. PMID: 30877063 Review.
-
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors.Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1311-1325. doi: 10.1080/17425255.2021.2004116. Epub 2021 Nov 26. Expert Opin Drug Metab Toxicol. 2021. PMID: 34743659 Review.
-
Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule _targeted anticancer drugs.Cancer Chemother Pharmacol. 2020 Jun;85(6):1015-1027. doi: 10.1007/s00280-020-04076-2. Epub 2020 May 18. Cancer Chemother Pharmacol. 2020. PMID: 32424570 Review.
Cited by
-
Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation.Int J Mol Sci. 2024 Feb 4;25(3):1887. doi: 10.3390/ijms25031887. Int J Mol Sci. 2024. PMID: 38339163 Free PMC article.
-
Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails.J Enzyme Inhib Med Chem. 2022 Dec;37(1):1257-1277. doi: 10.1080/14756366.2022.2068148. J Enzyme Inhib Med Chem. 2022. PMID: 35484863 Free PMC article.
-
Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges.Front Pharmacol. 2023 Aug 30;14:1244597. doi: 10.3389/fphar.2023.1244597. eCollection 2023. Front Pharmacol. 2023. PMID: 37711177 Free PMC article. Review.
-
Discovery of Hordenine as a Potential Inhibitor of Pyruvate Dehydrogenase Kinase 3: Implication in Lung Cancer Therapy.Biomedicines. 2020 May 14;8(5):119. doi: 10.3390/biomedicines8050119. Biomedicines. 2020. PMID: 32422877 Free PMC article.
-
Effects of rigidity on the selectivity of protein kinase inhibitors.Eur J Med Chem. 2018 Feb 25;146:519-528. doi: 10.1016/j.ejmech.2018.01.053. Epub 2018 Jan 31. Eur J Med Chem. 2018. PMID: 29407977 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources